Shop

Showing 945–960 of 1319 results

Article: Overcoming intrinsic and acquired resistance to EGFR-targeting agents in cancer treatment: focus on identification of predictive biomarkers and novel therapeutic strategies
€3.03 Add to cart
Article: Overview of trials running in the Benelux
€3.03 Add to cart
Article: Overview of trials running in the Benelux
€3.03 Add to cart
Article: Overview of trials running in the Benelux
€3.03 Add to cart
Article: Overview of trials running in the Benelux
€3.03 Add to cart
Article: Overview of trials running in the Benelux
€3.03 Add to cart
Article: P.01 A LUNG CANCER-DERIVED CRAF MUTATION IS ERK PATHWAY ACTIVATING AND PREDICTS SENSITIVITY TO COMBINED TYPE II RAF AND MEK INHIBITION
€3.03 Add to cart
Article: P.01 Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer (NSCLC) cells
€3.03 Add to cart
Article: P.02 Polymorphisms in the Von Hippel Lindau gene are associated with poor overall survival in metastatic clear-cell renal cell carcinoma patients treated with VEGFR tyrosine kinase inhibitors
€3.03 Add to cart
Article: P.02 THE ROLE OF TOPOISOMERASE II-A (TOPO IIA) AS A PREDICTIVE FACTOR FOR RESPONSE TO NEOADJUVANT ANTHRACYCLINES BASED CHEMOTHERAPY IN LOCALLY ADVANCED BREAST CANCER
€3.03 Add to cart
Article: P.03 Selective internal radiotherapy: a 5-year single-center experience
€3.03 Add to cart
Article: P.03 THE TRITON CLINICAL TRIAL PROGRAMME: EVALUATION OF THE POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR RUCAPARIB IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY
€3.03 Add to cart
Article: P.04 ENDOTHELIAL CELL METABOLISM BLOCKADE TO INDUCE TUMOR VESSEL NORMALIZATION AND IMPROVE CURRENT IMMUNOTHERAPY
€3.03 Add to cart
Article: P.04 Osteonecrosis of the Jaw Incidence in Patients Treated Sequentially with Bisphosphonates and Denosumab
€3.03 Add to cart
Article: P.05 Incidence of osteonecrosis of the jaw in patients both treated with bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors
€3.03 Add to cart
Article: P.05 LONG-TERM CLINICAL OUTCOME AND SURVIVORSHIP ISSUES OF HIGH GRADE BONE SARCOMAS
€3.03 Add to cart

Article: Overcoming intrinsic and acquired resistance to EGFR-targeting agents in cancer treatment: focus on identification of predictive biomarkers and novel therapeutic strategies

Article: Overview of trials running in the Benelux

Article: Overview of trials running in the Benelux

Article: Overview of trials running in the Benelux

Article: Overview of trials running in the Benelux

Article: Overview of trials running in the Benelux

Article: P.01 A LUNG CANCER-DERIVED CRAF MUTATION IS ERK PATHWAY ACTIVATING AND PREDICTS SENSITIVITY TO COMBINED TYPE II RAF AND MEK INHIBITION

Article: P.01 Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer (NSCLC) cells

Article: P.02 Polymorphisms in the Von Hippel Lindau gene are associated with poor overall survival in metastatic clear-cell renal cell carcinoma patients treated with VEGFR tyrosine kinase inhibitors

Article: P.02 THE ROLE OF TOPOISOMERASE II-A (TOPO IIA) AS A PREDICTIVE FACTOR FOR RESPONSE TO NEOADJUVANT ANTHRACYCLINES BASED CHEMOTHERAPY IN LOCALLY ADVANCED BREAST CANCER

Article: P.03 Selective internal radiotherapy: a 5-year single-center experience

Article: P.03 THE TRITON CLINICAL TRIAL PROGRAMME: EVALUATION OF THE POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR RUCAPARIB IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY

Article: P.04 ENDOTHELIAL CELL METABOLISM BLOCKADE TO INDUCE TUMOR VESSEL NORMALIZATION AND IMPROVE CURRENT IMMUNOTHERAPY

Article: P.04 Osteonecrosis of the Jaw Incidence in Patients Treated Sequentially with Bisphosphonates and Denosumab

Article: P.05 Incidence of osteonecrosis of the jaw in patients both treated with bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors

Article: P.05 LONG-TERM CLINICAL OUTCOME AND SURVIVORSHIP ISSUES OF HIGH GRADE BONE SARCOMAS